OMER, Israel, July 2, 2013 /PRNewswire/ --
Medigus Ltd (TASE:MDGS) announced today that it had approved the first order for SRS™ systems in the United States. The systems are expected to be used in procedures for the treatment of gastroesophageal reflux disease (GERD) at Columbia University Medical Center - New York Presbyterian Hospital during the next several weeks, constituting the first commercial use of the SRS™ system in the United States.
Elazar Sonnenschein, CEO of Medigus: "We are excited at the prospect of the first commercial use of the system in the US. One of our primary goals is the penetration into the strategic US market, in which up to 12 million patients may be in need of the treatment offered by the SRS™. In parallel we are pursuing marketing goals in Europe as well as Canada, having received CE and Health Canada approvals in these two important markets. These efforts are part of our long-term goal of positioning Medigus as a leader in the field of minimally-invasive surgical devices offering an alternative to current surgical procedures."
About Medigus Ltd.
Medigus (TASE: MDGS) is a medical device company headquartered in Omer, Israel, specializing in developing innovative endoscopic procedures and devices. Medigus is a pioneer developer of a unique proprietary endoscopic device for the treatment of GERD, one of the most common chronic diseases in the western world. In addition, Medigus has developed the world's smallest camera for endoscopic use as well as for other medical and industrial applications.
Based on its proprietary technologies, Medigus designs and manufactures endoscopy systems for partner companies, including major players in the medical device industry. Medigus has an advanced technology platform that includes all necessary elements for performing a wide range of endoscopic procedures. The platform includes multiple rigid, semi-flexible and flexible video endoscopes, as well as respective endoscopy suites.
Hayden/ MS-IR LLC
SOURCE Medigus Ltd